American Conference

NanOlogy Clinical and Preclinical Immune Data Presented at NACLC and SITC

Retrieved on: 
Tuesday, December 19, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Spleen, Immunotherapy, Conference, TME, LSAM, American Conference, Flow cytometry, Blood, Mouse, Paclitaxel, Immunomodulation, Society, Poster, Safety, Lung cancer, NK, NMIBC, SITC, Vaccine

NanOlogy LLC , a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.

Key Points: 
  • NanOlogy LLC , a clinical-stage oncology company, reports data presented as posters during recent oncology conferences.
  • The poster was authored by clinical investigators Hiren Mehta , Abhishek Biswas , Sarah Wang , Jason Akulian , Christine Argento , et.al.
  • Summarizing presented data:
    The early phase lung cancer trial demonstrated safety and tolerability of intratumoral (IT) LSAM-PTX in combination with various concurrent therapies, including systemic immunotherapy.
  • Summarizing presented data:
    Immunophenotyping in 3 diverse tumor settings found commonalities in antitumor immunomodulation following local LSAM-DTX, including changes in T cells and MDSCs.

Applied BioMath, LLC Announces Participation at the 14th American Conference on Pharmacometrics

Retrieved on: 
Thursday, November 2, 2023
Association of Applied Biologists, Mathematical and theoretical biology, American Conference, Conference, Doctor of Philosophy, R, EFA, Statistics, National Harbor, Maryland, Tourism, Management, MD

Applied BioMath will host a pre-conference workshop entitled, "Practical Application of MID3 to Inform Early Drug Discovery Decisions Using Applied BioMath Assess™" on Sunday, November 5th from 1:00 - 5:00p.m.

Key Points: 
  • Applied BioMath will host a pre-conference workshop entitled, "Practical Application of MID3 to Inform Early Drug Discovery Decisions Using Applied BioMath Assess™" on Sunday, November 5th from 1:00 - 5:00p.m.
  • The workshop will provide an understanding of the Early Feasibility Assessment (EFA) methodology and teach participants how to use Applied BioMath Assess™ to gain insight into project feasibility early in R&D.
  • "We are looking forward to the pre-conference workshop, poster presentations, and celebrating the achievement of Dr. Rendary at ACoP14," said John Burke, PhD, Co-founder, President and CEO of Applied BioMath.
  • "The scientific program highlights the advances of quantitative approaches in drug and therapeutic R&D and we look forward to the scientific discussions with the attendees."

Atalan Tech Secures Financing to Transform Healthcare with AI-Powered Clinician Well-Being Solutions

Retrieved on: 
Thursday, October 5, 2023
Well, Partnership, American Conference, Machine learning, AI, Health, Entrepreneurship, Growth, Marketing, Conference, Patient, SSM Health, Pharmaceutical industry, Nursing

BOSTON, Oct. 5, 2023 /PRNewswire-PRWeb/ -- Atalan Tech, a women-led, mission-driven company at the forefront of AI technology for predicting and preventing clinician burnout and turnover in healthcare systems, is pleased to announce the successful completion of its growth financing. The round was led by Excelerate Health Ventures and OCA Ventures, among other notable investors.

Key Points: 
  • We are thrilled to have secured $2.5 million in our Seed Round, a strong testament to the mission Atalan Tech embodies.
  • We believe in putting the care back into healthcare by empowering healthcare leaders to proactively manage the lifecycle of clinician and nurse well-being and retention.
  • Tiffany Chan, Co-Founder and CEO of Atalan Tech, expressed her excitement, stating, "We are thrilled to have secured $2.5 million in our Seed Round, a strong testament to the mission Atalan Tech embodies.
  • We believe in putting the care back into healthcare by empowering healthcare leaders to proactively manage the lifecycle of clinician and nurse well-being and retention."

Gale and NACBS Award Fellowships to Five Scholars to Support British Studies and Decolonization/Diaspora Research

Retrieved on: 
Tuesday, September 12, 2023
Desire, Knowledge, Learning, Network, Jacobitism, Partnership, British Library, Archive, University, Gale (publisher), British Empire, Negro, Lab, Teaching, Curriculum, University of Texas at Austin, Revolution, Social Life, Research, NTW, Earl, Activism, DH, Bright Young Things (film), North American Conference on Chinese Linguistics, Joyce Hyser, American Revolution, Negro Theatre Workshop, Ogle, Colonialism, Coffee, Longevity, American Conference, Achievement Medal, Interwar Britain, Conference, British studies, Nursing, Love

FARMINGTON HILLS, Mich. and NEW YORK, Sept. 12, 2023 /PRNewswire/ -- Gale, part of Cengage Group, in partnership with the North American Conference on British Studies (NACBS), has awarded fellowships to five researchers. The Gale-NACBS Non-Residential Fellowships support research or teaching projects that rely on Gale Primary Sources and use digital humanities (DH) methodologies. The fellowships aim to help scholars expand the fields of British and decolonization studies for research and teaching as well as help support early career researchers develop the DH skills they need for future academic success and longevity.

Key Points: 
  • The Gale-NACBS Non-Residential Fellowships support research or teaching projects that rely on Gale Primary Sources and use digital humanities (DH) methodologies.
  • The fellowships aim to help scholars expand the fields of British and decolonization studies for research and teaching as well as help support early career researchers develop the DH skills they need for future academic success and longevity.
  • "The NACBS is thrilled to partner with Gale to provide scholars with the opportunity to incorporate new digital humanities applications into their research in British Studies," said Deborah Valenze, president at NACBS.
  • In offering fellowships, to scholars in multiple disciplines, Gale is increasing access to text and data mining tools and furthering opportunities in both research and teaching.

Crystal IS and Asahi Kasei Announce First 4-inch Aluminum Nitride Substrate

Retrieved on: 
Wednesday, August 9, 2023
Technology, Mobile, Wireless, Other Science, Research, Utilities, Alternative Energy, Energy, Automotive, Health, Satellite, General Health, Nanotechnology, Science, Telecommunications, General Automotive, Networks, Engineering, Hardware, Automotive Manufacturing, Electronic Design Automation, Aerospace, Manufacturing, Consumer Electronics, Aluminium nitride, Light-emitting diode, Advanced Science, Thermal conductivity, Crystal, UVC, Asahi Kasei, Multimedia, Boule (crystal), American Conference, Crystal growth, Conference, RF, Aluminium, Printed circuit board

Crystal IS, an Asahi Kasei company, today announced the successful production of a 4-inch (100 mm) diameter single-crystal aluminum nitride (AlN) substrate.

Key Points: 
  • Crystal IS, an Asahi Kasei company, today announced the successful production of a 4-inch (100 mm) diameter single-crystal aluminum nitride (AlN) substrate.
  • View the full release here: https://www.businesswire.com/news/home/20230809402685/en/
    Crystal IS 4-inch (100 mm) diameter bulk aluminum nitride substrate comparison.
  • “We are extremely excited to announce the achievement of a 4-inch bulk aluminum nitride substrate,” said Dr. Naohiro Kuze, Executive Fellow at the Research Laboratory of Advanced Science and Technology, Asahi Kasei.
  • For more information on Aluminum Nitride and Crystal IS products, visit cisuvc.com or contact [email protected] .

Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Wednesday, July 12, 2023
ACT, Part 1, Triple-negative breast cancer, TNBC, Index, Probability, HIV, VL, Pharmacy, Part, Diabetic neuropathy, DLT, Weakness, BOR, ART, Research, Observation, ASCO, Synthetic control method, EBITDA, Endometrial cancer, Patient, Treatment, Marathon Asset Management, Part Two, Viral load, MTD, SMR, Growth, Diagnosis, Toxic leukoencephalopathy, R, CD4, Ovarian cancer, American Conference, Hand, Conference, SD, Disease, PR, Safety, Prostate cancer, SORT1, Fine chemical, Pharmaceutical industry, Vaccine

For the second quarter of fiscal 2023, net sales of EGRIFTA SV® were $10,853,000 compared to $11,416,000 in the second quarter of fiscal 2022, representing a decrease of 4.9% year-over-year.

Key Points: 
  • For the second quarter of fiscal 2023, net sales of EGRIFTA SV® were $10,853,000 compared to $11,416,000 in the second quarter of fiscal 2022, representing a decrease of 4.9% year-over-year.
  • Trogarzo® net sales in the second quarter of fiscal 2023 amounted to $6,696,000 compared to $7,852,000 for the same quarter of 2022, representing a decrease of 14.7% year-over-year.
  • We ended the second quarter of fiscal 2023 with $25,369,000 in cash, bonds and money market funds.
  • In the second quarter of fiscal 2023, changes in operating assets and liabilities had a positive impact on cash flow of $4,643,000 (2022-positive impact of $10,701,000).

Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison

Retrieved on: 
Thursday, May 4, 2023
AIDS Healthcare Foundation, Database, University, Senior, HIV, VL, Clinical trial, Chapel Hill, ART, University of North Carolina academic-athletic scandal, Observation, Synthetic control method, AIDS, Ibalizumab, EHR, Data, Patient, Viral load, TSX, SMR, CD4, American Conference, Conference, Treatment, Disease, Vaccine, Pharmaceutical industry

The ibalizumab study is thought to be the first matching-adjusted indirect treatment comparison (MAIC) study in HIV, an approach designed to facilitate a closely matched comparison from a synthesized, real-world population, when randomization to a control arm would be impractical or unethical.

Key Points: 
  • The ibalizumab study is thought to be the first matching-adjusted indirect treatment comparison (MAIC) study in HIV, an approach designed to facilitate a closely matched comparison from a synthesized, real-world population, when randomization to a control arm would be impractical or unethical.
  • Despite ibalizumab trial participants having more severe disease at baseline than non-ibalizumab controls, ibalizumab was associated with superior virologic outcomes.
  • Additionally, the same significance emerged for maintaining viral suppression, which was 18 times lower for real-world non-ibalizumab regimens compared to ibalizumab.
  • For both durability analyses, confidence intervals were wide but statistically significant (SMR-weighted HR: 18.36; 95% CI: 2.48, 135.68).

Biosplice Announces Interim Data from Phase 3 Long-Term Extension Clinical Trial in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial

Retrieved on: 
Thursday, December 15, 2022
Conference, Physician, Protein, Clinical trial, Rheumatology, LOR, SAN, Biosplice Therapeutics, WOMAC, KL2, Safety, Science, Alternative splicing, CLK, American Conference, RNA transfection, Osteoarthritis, Knee, Cancer, Therapy, Injection, Biology, Patient, Pharmaceutical industry, Dietary supplement, Tutoring, MD

“We believe these unique data highlight lorecivivint’s promise to potentially provide structural benefit to the millions of patients suffering from osteoarthritis,” commented Biosplice Chief Medical Officer, Yusuf Yazici, MD.

Key Points: 
  • “We believe these unique data highlight lorecivivint’s promise to potentially provide structural benefit to the millions of patients suffering from osteoarthritis,” commented Biosplice Chief Medical Officer, Yusuf Yazici, MD.
  • We recently initiated our phase 3 OA-21 clinical trial and are enrolling subjects.
  • The primary efficacy objective of OA-07 is to measure the disease-modifying potential of lorecivivint over multiple years and injections.
  • The OA-21 phase 3 clinical trial is designed as a 16-week study with a primary endpoint of Pain NRS at 12 weeks.

Current Launches Lifeshield Lighting for Complex Spaces

Retrieved on: 
Tuesday, December 6, 2022
Hardware, Other Construction & Property, Technology, Residential Building & Real Estate, Commercial Building & Real Estate, Hospitals, Construction & Property, Retail, Surgery, Building Systems, Health, Home Goods, Ford Torino engine specifications, Amber, Conference, IP, Visual acuity, ISO, Light, 3G, NSF, American Conference, IEC, ANSI, Health, American Conference of Governmental Industrial Hygienists, Risk management

Current is expanding its portfolio once again to include the Lifeshield brand which offers lighting for health care, behavioral, vandal and cleanroom environments.

Key Points: 
  • Current is expanding its portfolio once again to include the Lifeshield brand which offers lighting for health care, behavioral, vandal and cleanroom environments.
  • Effectively lighting complex spaces requires robust products that provide consistent performance, flexible options and that meet strict standards such as ISO, NSF, IP, IK10 and ANSI 3G.
  • Now Current delivers all these benefits and more in one LED lighting portfolio for health care settings, public spaces and other vulnerable areas.
  • Including our considerable experience, production capabilities and logistics footprint, we are perfectly positioned to service the complex lighting market.

Christie CounterAct UR10 added to line of UVC disinfection fixtures

Retrieved on: 
Friday, October 21, 2022
American Conference, ACGIH, Government, Conference, Android, Organization, Ventilation, Regulation of tobacco by the U.S. Food and Drug Administration, American Rescue Plan Act of 2021, Technology, Ushio, Inc., Food, Christie's, Counteraction principle, Christie, UVGI, Disinfectant, IOS, Patent, Safety, Spread, Atmosphere, UVC, COVID-19, USD, James S. Brady Press Briefing Room, School, Heating, ventilation, and air conditioning, Pharmaceutical industry, Vaccine, Animal, Pandemic

CYPRESS, Calif., Oct. 21, 2022 /PRNewswire-PRWeb/ -- As we continue to see relaxed COVID-19 restrictions — leaving the onus of safety in the hands of business operators, owners and facilities managers — global visual technologies company Christie® is pleased to introduce its newest CE- and UL- certified commercial UVC-LED disinfection light fixture for occupied, indoor spaces. Christie CounterAct™ UR10 with UVC-LED and patented Care222® far-UVC - plus visible light, in a single unit, is recommended for commercial offices, government facilities, schools, transit hubs, retail shops, medical buildings — for enhanced and safe airborne and surface disinfection wherever people gather indoors, in public places.

Key Points: 
  • Combining filtered Care222 far-UVC light with upper room high-power mercury-free UVC-LED, CounterAct UR10 is an evolution in technology for treating both surfaces and air in occupied indoor spaces.
  • "With our latest addition to the Christie CounterAct line of UVC disinfection fixtures, we are excited to continue to help organizations create greater confidence in indoor spaces as we return to in person interaction," said Brent Peckover, director, industrial applications, Christie.
  • Peckover explains, "UVC disinfection systems should be seamless and require no day-to-day user interaction while effectively inactivating pathogens in the occupied space."
  • Christie has filed one or more patent application(s) related to technical innovations in the Christie CounterAct UR10.